SGS is pleased to announce the recruitment of the first participants in the US who will be taking part in a multinational clinical trial of a potential drug candidate for those suffering with COVID-19 related respiratory failure.
The recruitment follows SGS's recent announcement of its selection by French biotech company Biophytis to conduct its COVA study – a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure.
